IFNA2 and neoplasm: Initially approved for use in melanoma, IFNα2 was subsequently associated with tumor regression and/or prolonged survival in a diverse hematological and solid malignancies including myeloma, lymphomas, renal cell and bladder carcinomas and Kaposi sarcoma[54].